What happened with SIGA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
SIGA Technologies Inc. supplies governments with TPOXX to prepare for smallpox emergencies. The U.S. Government is its main customer, buying oral and intravenous TPOXX for the Strategic National Stockpile. Product deliveries generate most revenue; its contract with the Biomedical Advanced Research and Development Authority (BARDA) also pays for development, manufacturing support and post-approval work. Foreign governments and government-affiliated entities buy oral TPOXX, sometimes through distributors, but contribute a smaller share of revenue.
The business depends heavily on U.S. Government procurement. Purchases require government funding, and the government decides whether to exercise contract options. Continued stockpile supply work also depends on securing replacement contracts, which are not guaranteed.
SIGA has no manufacturing facilities of its own and relies on outside suppliers to produce, test and package TPOXX. It is transferring intravenous production to a new manufacturer whose facility needs FDA approval. In the United States, only the oral and intravenous formulations are approved, both for smallpox treatment; SIGA cannot sell its pediatric liquid formulation or other additional formulations without the required approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
SIGA’s results hinge on government purchases of TPOXX, particularly BARDA orders, while Bavarian Nordic, absent from this list, is another important rival for medical-countermeasure funding.
Emergent Biosolutions, Inc. competes for the government preparedness budgets that pay SIGA for its smallpox antiviral TPOXX, selling governments its own smallpox medical countermeasures. Watch Emergent’s smallpox-product procurement awards for signs of where governments are directing preparedness spending.
Emergent Biosolutions, Inc. earningsEBS
Emergent BioSolutions' report can show whether governments are buying more of its smallpox countermeasures, which compete for preparedness budgets that also fund SIGA's TPOXX.
Look for Emergent BioSolutions' disclosed smallpox-product awards and sales, not just its total revenue, and compare them with SIGA's reported TPOXX deliveries. Stronger awards or sales would show governments directing more money to a product competing with TPOXX; weaker activity would mean less evidence of that budget competition, not proof SIGA's demand has risen. The conclusion is how strong a competing claim on preparedness spending this report shows.
SIGA Technologies Inc. earningsThis company
SIGA sells TPOXX mainly to governments, and this report will show whether product deliveries and government-funded support work are still turning into recognized revenue.
Read product sales and supportive-services revenue alongside research and development revenue. Higher product revenue backed by TPOXX deliveries accepted by customers would show government procurement converting into sales; weak product revenue could mean fewer or later recognized deliveries, not necessarily weaker demand. R&D revenue reflects funded work performed and can include estimates, so it is not a product shipment. The conclusion is whether government procurement is still converting into revenue SIGA recognizes.
